NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
NovoCure's pe ratio was 734.3× on Mar 31, 2021.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2021 | Mar 31, 2021 | 734.3× | −176.4 |
| 2020 | Dec 31, 2020 | 910.7× | – |
See a number that looks wrong?